Ethicon Exec: FDA Mesh Safety Notice Could Have Long-Term Impact
This article was originally published in The Gray Sheet
Executive Summary
A manufacturer of surgical mesh devices for minimally invasive gynecological procedures is worried that a recent FDA safety alert may slow long-term adoption of the products even after better data is available
You may also be interested in...
Surgical mesh alert
FDA warns physicians and consumers Oct. 20 about complications associated with surgical mesh devices to treat pelvic organ prolapse and stress urinary incontinence. The agency said it received more than 1,000 reports from nine manufacturers of problems with transvaginal placement of the mesh devices, including erosion through vaginal epithelium, infection, pain and urinary problems. Physicians should obtain specialized training in mesh placement techniques and monitor for complications, FDA advises. The agency also warned consumers about problems with surgical mesh for hernia repairs
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.